By Denny Jacob
Gilead Sciences raised its outlook for 2023.
The biopharmaceutical company forecast total sales between $26.7 billion and $26.9 billion versus its prior guidance in the range of $26.3 billion and $26.7 billion.
Total sales excluding Veklury were guided between $24.8 billion and $25 billion. It previously set a range between $24.6 billion and $25 billion. Veklury sales are expected to reach $1.9 billion versus a prior estimate of $1.7 billion.
Gilead also forecast adjusted earnings per-share in the range of $6.65 and $6.85 compared to prior guidance of $6.45 a share and $6.80 a share.
Write to Denny Jacob at denny.jacob@wsj.com
Read the full article here